文献速递预防保健、筛查与疫苗老年与多病共存慢病管理

北欧国家≥50岁成人二价BA.4-5与BA.1 mRNA加强疫苗比较效果:全国队列研究

Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study.
PubMed 文献 · BMJ · 2023-07-25

该研究采用目标试验模拟的全国队列分析,纳入丹麦、芬兰、挪威和瑞典2022年7月1日至2023年4月10日≥50岁已接种至少三剂新冠疫苗者。结果显示,第四剂二价BA.4-5或BA.1 mRNA加强疫苗均可降低新冠相关住院和死亡风险;直接比较两种二价疫苗的效果无显著差异。

要点

  • 第四剂二价BA.4-5或BA.1加强疫苗可降低≥50岁成人新冠相关住院和死亡风险。
  • 直接比较BA.4-5与BA.1第四剂加强疫苗,住院和死亡风险无显著差异。
  • 保护效果在接种后六个月内似有维持,仅轻度减弱。

核心结论

  • ≥50岁成人接种第四剂二价BA.4-5或BA.1 mRNA加强疫苗与新冠相关住院和死亡风险降低相关。
  • 直接比较两种二价加强疫苗,保护效果无显著差异,任何潜在差异在绝对数上很可能非常小。

研究设计与样本

  • 全国队列分析,采用目标试验模拟,覆盖丹麦、芬兰、挪威和瑞典2022年7月1日至2023年4月10日。
  • 纳入≥50岁且已接种至少三剂新冠疫苗者;共1 634 199人接种第四剂二价BA.4-5加强疫苗,1 042 124人接种第四剂二价BA.1加强疫苗。

主要发现

  • 与接种三剂相比,第四剂二价BA.4-5加强疫苗对新冠相关住院的比较疫苗有效性为67.8%(95%CI 63.1%至72.5%),三个月随访风险差为每10万人-91.9(95%CI -152.4至-31.4)(289 vs 893事件)。
  • 与接种三剂相比,第四剂二价BA.1加强疫苗对新冠相关住院的比较疫苗有效性为65.8%(95%CI 59.1%至72.4%),风险差为每10万人-112.9(95%CI -179.6至-46.2)(332 vs 977事件)。
  • 第四剂二价BA.4-5加强疫苗对新冠相关死亡比较疫苗有效性为69.8%(95%CI 52.8%至86.8%),风险差为每10万人-34.1(95%CI -40.1至-28.2)(93 vs 325事件)。
  • 第四剂二价BA.1加强疫苗对新冠相关死亡比较疫苗有效性为70.0%(95%CI 50.3%至89.7%),风险差为每10万人-38.7(95%CI -65.4至-12.0)(86 vs 286事件)。
  • 直接比较第四剂二价BA.4-5与BA.1加强疫苗,新冠相关住院三个月比较疫苗有效性为-14.9%(95%CI -62.3%至32.4%),风险差为每10万人10.0(95%CI -14.4至34.4)(802 vs 932未加权事件);新冠相关死亡比较疫苗有效性为-40.7%(95%CI -123.4%至42.1%),风险差为每10万人8.1(95%CI -3.3至19.4)(229 vs 243未加权事件)。

关键数值与推荐

  • 第四剂二价BA.4-5加强疫苗对新冠相关住院比较疫苗有效性67.8%(95%CI 63.1%至72.5%),风险差每10万人-91.9(95%CI -152.4至-31.4)。
  • 第四剂二价BA.1加强疫苗对新冠相关住院比较疫苗有效性65.8%(95%CI 59.1%至72.4%),风险差每10万人-112.9(95%CI -179.6至-46.2)。
  • 第四剂二价BA.4-5加强疫苗对新冠相关死亡比较疫苗有效性69.8%(95%CI 52.8%至86.8%),风险差每10万人-34.1(95%CI -40.1至-28.2)。
  • 第四剂二价BA.1加强疫苗对新冠相关死亡比较疫苗有效性70.0%(95%CI 50.3%至89.7%),风险差每10万人-38.7(95%CI -65.4至-12.0)。
  • 直接比较两种第四剂二价加强疫苗,新冠相关住院比较疫苗有效性-14.9%(95%CI -62.3%至32.4%),死亡比较疫苗有效性-40.7%(95%CI -123.4%至42.1%)。

临床怎么用

  • 对于≥50岁已完成基础免疫和第一剂加强的成人,可考虑接种第四剂二价BA.4-5或BA.1 mRNA加强疫苗以降低新冠相关住院和死亡风险。
  • 选择二价BA.4-5或BA.1加强疫苗时,无需因保护效果差异而偏好某一种,两者直接比较无显著差异。
  • 接种后保护效果似可维持至六个月,仅轻度减弱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the effectiveness of the bivalent mRNA booster vaccines containing the original SARS-CoV-2 and omicron BA.4-5 or BA.1 subvariants as the fourth dose against severe covid-19. DESIGN: Nationwide cohort analyses, using target trial emulation. SETTING: Denmark, Finland, Norway, and Sweden, from 1 July 2022 to 10 April 2023. PARTICIPANTS: People aged ≥50 years who had received at least three doses of covid-19 vaccine (that is, a primary course and a first booster). MAIN OUTCOME MEASURES: The Kaplan-Meier estimator was used to compare the risk of hospital admission and death related to covid-19 in people who received a bivalent Comirnaty (Pfizer-BioNTech) or Spikevax (Moderna) BA.4-5 or BA.1 mRNA booster vaccine as a fourth dose (second booster) with three dose (first booster) vaccinated people and between four dose vaccinated people. RESULTS: A total of 1 634 199 people receiving bivalent BA.4-5 fourth dose booster and 1 042 124 receiving bivalent BA.1 fourth dose booster across the four Nordic countries were included. Receipt of a bivalent BA.4-5 booster as a fourth dose was associated with a comparative vaccine effectiveness against admission to hospital with covid-19 of 67.8% (95% confidence interval 63.1% to 72.5%) and a risk difference of -91.9 (95% confidence interval -152.4 to -31.4) per 100 000 people at three months of follow-up compared with having received three doses of vaccine (289 v 893 events). The corresponding comparative vaccine effectiveness and risk difference for bivalent BA.1 boosters (332 v 977 events) were 65.8% (59.1% to 72.4%) and -112.9 (-179.6 to -46.2) per 100 000, respectively. Comparative vaccine effectiveness and risk difference against covid-19 related death were 69.8% (52.8% to 86.8%) and -34.1 (-40.1 to -28.2) per 100 000 for bivalent BA.4-5 booster (93 v 325 events) and 70.0% (50.3% to 89.7%) and -38.7 (-65.4 to -12.0) per 100 000 for BA.1 booster (86 v 286) as a fourth dose. Comparing bivalent BA.4-5 and BA.1 boosters as a fourth dose directly resulted in a three month comparative vaccine effectiveness and corresponding risk difference of -14.9% (-62.3% to 32.4%) and 10.0 (-14.4 to 34.4) per 100 000 people for admission to hospital with covid-19 (802 v 932 unweighted events) and -40.7% (-123.4% to 42.1%) and 8.1 (-3.3 to 19.4) per 100 000 for covid-19 related death (229 v 243 unweighted events). The comparative vaccine effectiveness did not differ across sex and age (</≥70 years) and seemed to be sustained up to six months from the day of vaccination with modest waning. CONCLUSION: Vaccination with bivalent BA.4-5 or BA.1 mRNA booster vaccines as a fourth dose was associated with reduced rates of covid-19 related hospital admission and death among adults aged ≥50 years. The protection afforded by the bivalent BA.4-5 and BA.1 boosters did not differ significantly when directly compared, and any potential difference would most likely be very small in absolute numbers.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Andersson NW, Thiesson EM, Baum U, et al. Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study. BMJ. 2023. PMID: 37491022. doi:10.1136/bmj-2022-075286

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。